FTH1 mRNA–Protein Discordance in Cardiac Ferroptosis: Multilayer Posttranscriptional and Degradative Control
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/8306021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Feng Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi, Chi…. Hauptthemen laut MEDLINE: Ferroptosis, RNA, Messenger, Oxidoreductases, Ferritins. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Ferritin heavy Chain 1 (FTH1) is a key protective factor against ferroptosis in the heart, yet its protein abundance can diverge from transcript levels in cardiac ferroptosis contexts. Since resistance to ferroptosis depends on FTH1 protein abundance rather than transcript levels and its ferroxidase activity cannot be readily compensated by other ferritin subunits, this mismatch is functionally consequential. This review organizes the evidence into three regulatory layers acting downstream of transcription. Iron regulatory protein/iron‐responsive element (IRP/IRE) signaling gates ribosome recruitment at the 5 ′ ‐untranslated region before translation begins. Epitranscriptomic marks and RNA‐binding proteins (RBPs) then route the transcript toward decay or translation, with the N 6 ‐methyladenosine (m 6 A) reader YTHDF2 acting in opposite directions across cardiac contexts. Finally, nuclear receptor Coactivator 4 (NCOA4) delivers assembled ferritin for lysosomal degradation, depleting FTH1 protein independently of transcript level. Together, these mechanisms provide an integrated framework for understanding the mRNA–protein discordance of FTH1 and its contribution to cardiac ferroptosis susceptibility. We also discuss how this framework may inform layer‐specific therapeutic strategies and identify the measurements that are missing (labile iron pool, ferritin iron loading, and ferritinophagic flux) before mechanistic insight can translate into clinical cardioprotection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi, China, njmu.edu.cn.
ORCID-Profile: Feng Zhou, Jia-Bin Zhou, Yi-Qing Yan, Tian-Peng Wei, Yi-Fan Yang, Ru-Xing Wang
Förderung
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Zhou, F., Zhou, J. B., Yan, Y. Q., Wei, T. P., Wu, D., Yang, Y. F., & Wang, R. X. (2026). FTH1 mRNA–Protein Discordance in Cardiac Ferroptosis: Multilayer Posttranscriptional and Degradative Control. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/8306021
Vancouver
Zhou F, Zhou JB, Yan YQ, Wei TP, Wu D, Yang YF, et al. FTH1 mRNA–Protein Discordance in Cardiac Ferroptosis: Multilayer Posttranscriptional and Degradative Control. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/8306021
BibTeX
@article{Zhou2026,
author = {Zhou, Feng and Zhou, Jia-Bin and Yan, Yi-Qing and Wei, Tian-Peng and Wu, Dan and Yang, Yi-Fan and Wang, Ru-Xing},
title = {FTH1 mRNA–Protein Discordance in Cardiac Ferroptosis: Multilayer Posttranscriptional and Degradative Control},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/8306021}
}
EUVIMED